<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445871</url>
  </required_header>
  <id_info>
    <org_study_id>1708155</org_study_id>
    <secondary_id>2017-004348-39</secondary_id>
    <nct_id>NCT03445871</nct_id>
  </id_info>
  <brief_title>Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate</brief_title>
  <acronym>POLYGLU</acronym>
  <official_title>Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methotrexate (MTX) is the first-line treatment of rheumatoid arthritis (RA). In case of MTX&#xD;
      failure, it is discussed to start a Biologic Disease-modifying Antirheumatic Drug (bDMARDs)&#xD;
      according to the latest European recommendations of the EULAR. Before to add a Biologic&#xD;
      Disease-modifying Antirheumatic Drug (bDMARDs), an objective estimation of MTX impregnation&#xD;
      could be carried out by MTX polyglutamates (MTX-PG). In rheumatoid arthritis patients with&#xD;
      active disease estimated by DAS28 (Disease activity Score 28)&gt; 3.2 insufficiently controlled&#xD;
      by MTX subcutaneously and patients in remission obtained with a DAS 28 &lt;2.6 with methotrexate&#xD;
      prescribed since more than 6 months at stable dose for at least 3 months, a concentration of&#xD;
      MTX-PG will be achieved.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The assumption is the association between low methotrexate erythrocyte polyglutamate and low&#xD;
      clinical response in rheumatoid arthritis patients treated with subcutaneous injectable&#xD;
      methotrexate. Adherence to MTX will be assessed by the Compliance Questionnaire Rheumatology&#xD;
      (CQR). Measurement of this adherence could optimize MTX treatment prior to the use of&#xD;
      biotherapy which is costly with a lower infectious tolerance.&#xD;
&#xD;
      Correlation between its concentration and compliance assessed by CQR questionnaire will be&#xD;
      tested.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2018</start_date>
  <completion_date type="Actual">May 28, 2020</completion_date>
  <primary_completion_date type="Actual">May 28, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTX-PG concentration</measure>
    <time_frame>Hour 1</time_frame>
    <description>To compare MTX-PG concentration in patients with active rheumatoid arthritis and patients with rheumatoid arthritis in remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>different metabolites dosing of MTX-PG</measure>
    <time_frame>Hour 1</time_frame>
    <description>Analysis of different metabolites dosing of MTX-PG by High-performance liquid chromatography technical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CQR score</measure>
    <time_frame>Hour 1</time_frame>
    <description>Analysis of CQR score response</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients with active rheumatoid arthritis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with active rheumatoid arthritis will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with rheumatoid arthritis into remission</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with rheumatoid arthritis into remission will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood samples will be collected for measuring PG-MTX blood concentration.</description>
    <arm_group_label>Patients with active rheumatoid arthritis</arm_group_label>
    <arm_group_label>Patients with rheumatoid arthritis into remission</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CRQ</intervention_name>
    <description>Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.</description>
    <arm_group_label>Patients with active rheumatoid arthritis</arm_group_label>
    <arm_group_label>Patients with rheumatoid arthritis into remission</arm_group_label>
    <other_name>Compliance Rheumatology Questionnaire</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years and have social security affiliation.&#xD;
&#xD;
          -  Patients followed in the Rheumatology Department at the hospital of St Etienne.&#xD;
&#xD;
          -  Patients with rheumatoid arthritis and :&#xD;
&#xD;
               -  Either Rheumatoid arthritis patients in remission (DAS 28&lt;2.6) with MTX treatment&#xD;
                  for at least 6months, and with a stable dose for 3months.&#xD;
&#xD;
               -  Or patients with a High Disease Activity Rheumatoid Arthritis activity (DAS&#xD;
                  28&gt;3.2) with MTX treatment (≥ 15 mg/weeks), taking MTX treatment for at least&#xD;
                  6months with a stable subcutaneous weekly MTX injection (≥ 15 mg/weeks) treatment&#xD;
                  during the previous 3 months.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients treated with another conventional synthetic Disease Modifying Anti-Rheumatic&#xD;
             Drugs (csDMARD)&#xD;
&#xD;
          -  Another diagnostic than rheumatoid arthritis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert MAROTTE, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>February 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>July 31, 2020</last_update_submitted>
  <last_update_submitted_qc>July 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Erythrocyte polyglutamate</keyword>
  <keyword>Compliance Questionnaire Rheumatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

